About abvc biopharma - ABVC
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.
ABVC At a Glance
ABVC BioPharma, Inc.
44370 Old Warm Springs Boulevard
Fremont, California 94538
| Phone | 1-510-668-0881 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -7,908,554.00 | |
| Sector | Health Technology | Employees | 19 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ABVC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.802 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.102 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.076 |
ABVC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -416,239.684 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ABVC Liquidity
| Current Ratio | 0.406 |
| Quick Ratio | 0.406 |
| Cash Ratio | 0.226 |
ABVC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -55.30 |
| Return on Equity | -128.198 |
| Return on Total Capital | -53.835 |
| Return on Invested Capital | -111.58 |
ABVC Capital Structure
| Total Debt to Total Equity | 32.205 |
| Total Debt to Total Capital | 24.36 |
| Total Debt to Total Assets | 16.99 |
| Long-Term Debt to Equity | 14.406 |
| Long-Term Debt to Total Capital | 10.897 |